<DOC>
	<DOC>NCT00347048</DOC>
	<brief_summary>This study consists of a 2-week placebo-controlled double-blind inter-group efficacy study in moderate to severe refractory ulcerative colitis (UC) patients followed by a maximum of 12-week open-label efficacy and safety study in responders.</brief_summary>
	<brief_title>Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Moderate to severe refractory UC patients Disease activity: more than 4 times of stool a day, bloody stool, moderate to severe endoscopic finding Steroid resistance or dependence to meet at least one of the following condition:no efficacy with more than 40mg/day or 1mg/kg/day of steroid over at least 1 week, no efficacy with 3040mg/day of steroid over at least 2 weeks,exacerbation along with steroid reduction Mild or fulminant type Renal failure patients, hepatic failure patients Patients taking 6mercaptopurine, cyclosporin or other immunosuppressants within 12 weeks prior to entry Patients who received LCAP or GCAP within 2 weeks prior to entry Patients who changed the dose of steroid or started steroid within 2 weeks prior to entry. Patients who changed the dose of steroid or started steroid within 1 week prior to entry in case they received more than 40 mg/ day or 1mg/kg/day of steroid just before the study.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Ulcerative colitis</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>FK506</keyword>
	<keyword>treatment outcome</keyword>
</DOC>